Due to its significant market share and high gross margins in a structurally growing industry, ResMed has posted an average return on invested capital, or ROIC, of 20% over the last decade. We ...

ResMed stock is down today, even though the maker of CPAPs and other respiratory treatment devices had Street-beating Q2 ...

Its core business includes the development of devices for sleep apnea -- such as CPAP and APAP machines -- and digital health solutions. Key success factors for ResMed include maintaining ...

In a report released today, Brett Fishbin from KeyBanc maintained a Buy rating on Resmed (RMD – Research Report), with a price target of ...

In the wake of the U.S. Food and Drug Administration’s approval of Zepbound to treat moderate to severe obstructive sleep ...

An announcement from Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh ( ($AU:RMD) ) is now available. ResMed Inc has ...

The market got it wrong quite badly,” Bell Direct market analyst Grady Wulff said. “I wouldn’t say they are fully valued. There is a lot of headroom there to grow.” ResMed’s revenue rose ...

(RTTNews) - Resmed Inc (RMD) revealed a profit for its second quarter that increased from last year and beat the Street estimates. The company's earnings totaled $344.6 million, or $2.34 per share.

ResMed Inc . (NYSE:RMD) reported its financial results for the second quarter of fiscal year 2025, exceeding analysts' expectations with an earnings per share (EPS) of $2.43, surpassing the forecasted ...

The next Nintendo Direct is rumored for February 2025, focusing on upcoming games for the original Switch. The Switch 2 reveal showcased a bigger, more powerful console with upgraded features like ...